Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN73,8573,86-1,44
Msft0,58
Nokia4,6464,7770,34
IBM0,75
Mercedes-Benz Group AG51,4551,47-0,41
PFE0,99
07.06.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 06.06.2025 16:01:25
Eckert & Ziegler (EUZG.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
64,30 -3,96 -2,65 17 337
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiEckert & Ziegler SE
TickerEUZ
Kmenové akcie:Ordinary Shares
RICEUZG.DE
ISINDE0005659700
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.03.2025 1 094
Akcie v oběhu k 31.03.2025 20 848 583
MěnaEUR
Kontaktní informace
UliceRobert-Roessle-Str.10
MěstoBERLIN
PSČ13125
ZeměGermany
Kontatní osobaKarolin Riehle
Funkce kontaktní osobyInvestor Relations
Telefon49 309 410 840
Fax4930941084112
Kontatní telefon4930 941 084 138

Business Summary: Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Eckert & Ziegler SE revenues increased 1% to EUR68.2M. Net income before extraordinary items increased 7% to EUR9.7M. Revenues reflect Isotope Products segment increase of 2% to EUR33.8M. Net income benefited from Other operating expenses decrease of 60% to EUR1.2M (expense), General and administrative expenses decrease of 6% to EUR10.8M (expense).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Scientific & Precision Equipment
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYChemical Manufacturing
MGSECTORBasic Materials
NAICSOther Basic Inorganic Chemical Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSSurgical Appliance and Supplies Manufacturing
NAICSOffices of Other Holding Companies
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007All Other Basic Inorganic Chemical Mfg
NAICS2007Surgical Appliance & Supplies Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997All Other Basic Inorganic Chemical Manufacturing
NAICS1997Surgical Appliance and Supplies Manufacturing
SICIndust'L Inorganic Chemicals, Nec
SICPharmaceutical Preparations
SICSurgical Appliances And Supplies
SICHolding Companies, Nec



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardAndreas Eckert6507.06.2023
Chairman of the Executive BoardHarald Hasselmann5808.06.202301.01.2017
Deputy Chairman of the Supervisory BoardHelmut Grothe6531.07.201731.07.2017
Member of the Group Executive Committee, Isotope Products SegmentJoseph Hathcock-
Member of the Group Executive Committee, Medical Segment (Operations)Gunnar Mann5801.01.2025
Member of the Group Executive Committee, Isotope Products SegmentAna Ramirez-01.01.2023
Member of the Executive Board, Isotope Products SegmentFranklin Yeager-